| Literature DB >> 35675695 |
Nathaniel M Lewis1, Wesley H Self2, Manjusha Gaglani3,4, Adit A Ginde5, David J Douin5, H Keipp Talbot2, Jonathan D Casey2, Nicholas M Mohr6, Anne Zepeski6, Shekhar A Ghamande3, Tresa A McNeal3, Nathan I Shapiro7, Kevin W Gibbs8, D Clark Files8, David N Hager9, Arber Shehu9, Matthew E Prekker10, Heidi L Erickson10, Michelle N Gong11, Amira Mohamed11, Nicholas J Johnson12, Vasisht Srinivasan12, Jay S Steingrub13, Ithan D Peltan14, Samuel M Brown14, Emily T Martin15, Arnold S Monto15, Akram Khan15, Laurence W Busse16, Caitlin C Ten Lohuis16, Abhijit Duggal17, Jennifer G Wilson18, Alexandra June Gordon18, Nida Qadir19, Steven Y Chang19, Christopher Mallow20, Carolina Rivas20, Hilary M Babcock21, Jennie H Kwon21, Matthew C Exline22, Adam S Lauring23, Natasha Halasa2, James D Chappell2, Carlos G Grijalva2, Todd W Rice2, Jillian P Rhoads2, Ian D Jones2, William B Stubblefield2, Adrienne Baughman2, Kelsey N Womack2, Christopher J Lindsell2, Kimberly W Hart2, Yuwei Zhu2, Katherine Adams1, Manish M Patel1, Mark W Tenforde1.
Abstract
Background . Adults in the United States (US) began receiving the adenovirus vector coronavirus disease 2019 (COVID-19) vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in February 2021. We evaluated Ad26.COV2.S vaccine effectiveness (VE) against COVID-19 hospitalization and high disease severity during the first 10 months of its use. Methods . In a multicenter case-control analysis of US adults (≥18 years) hospitalized 11 March to 15 December 2021, we estimated VE against susceptibility to COVID-19 hospitalization (VEs), comparing odds of prior vaccination with a single dose Ad26.COV2.S vaccine between hospitalized cases with COVID-19 and controls without COVID-19. Among hospitalized patients with COVID-19, we estimated VE against disease progression (VEp) to death or invasive mechanical ventilation (IMV), comparing odds of prior vaccination between patients with and without progression. Results . After excluding patients receiving mRNA vaccines, among 3979 COVID-19 case-patients (5% vaccinated with Ad26.COV2.S) and 2229 controls (13% vaccinated with Ad26.COV2.S), VEs of Ad26.COV2.S against COVID-19 hospitalization was 70% (95% confidence interval [CI]: 63-75%) overall, including 55% (29-72%) among immunocompromised patients, and 72% (64-77%) among immunocompetent patients, for whom VEs was similar at 14-90 days (73% [59-82%]), 91-180 days (71% [60-80%]), and 181-274 days (70% [54-81%]) postvaccination. Among hospitalized COVID-19 case-patients, VEp was 46% (18-65%) among immunocompetent patients. Conclusions . The Ad26.COV2.S COVID-19 vaccine reduced the risk of COVID-19 hospitalization by 72% among immunocompetent adults without waning through 6 months postvaccination. After hospitalization for COVID-19, vaccinated immunocompetent patients were less likely to require IMV or die compared to unvaccinated immunocompetent patients. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2022.Entities:
Keywords: COVID-19; vaccine effectiveness; viral vector vaccines
Mesh：
Substances：
Year: 2022 PMID： 35675695 PMCID： PMC9214149 DOI： 10.1093/cid/ciac439
Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 20.999